A 52-year-old woman with HER2-positive metastatic breast cancer is being considered for trastuzumab versus lapatinib. Which clinical feature would best favor the use of lapatinib over trastuzumab?
See the options, answer & explanation
Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.
